April 15, 2008
A Lilly Drug Logs Success And Risks In Heart Trial
Prasugrel, Eli Lilly's experimental anticlotting drug, is found to reduce heart attacks in patients with heart disease by 24 percent compared with current standard treatment using Plavix; is also found to increase risks of severe bleeding and quadruples risk of fatality; editorial in New England Journal of Medicine, where studies are published, says that in carefully selected patients, prasugrel may be advance in treatment of patients with acute coronary syndrome; Lilly and co-developer Daiichi…
Trackback uri
http://www.glycoblog.com/8343/a-lilly-drug-logs-success-and-risks-in-heart-trial-124/trackback/
